New drug injection tested in patients with Tough-to-Treat lymphoma
NCT ID NCT06018129
Summary
This early-stage trial tested a new drug called GEN3017, given as an injection under the skin, for people with advanced Hodgkin and Non-Hodgkin lymphoma that had come back or stopped responding to other treatments. The main goals were to find a safe dose and see how the body handles the drug. The study was terminated early after enrolling only 9 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Helford Clinical Research Hospital
Duarte, California, 91010, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Peter MacCallum Cancer Institute trading as Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.